跳到正文
原文
Endpoints News 生物医药· Nicole DeFeudis·· 12 天前AI 评分50

Vir宣布慢性肝炎D药物组合在首个关键研究中取得成功

Vir says hepatitis D drug combination succeeds in first pivotal study

AI 导读

Vir Biotechnology 的慢性肝炎D治疗药物在首个关键研究中取得成功,与吉利德和Mirum Pharmaceuticals形成竞争。

正文

Vir Biotech­nol­o­gy’s chron­ic he­pati­tis D treat­ment has suc­ceed­ed in the first of three late-stage stud­ies, stok­ing com­pe­ti­tion with Gilead and Mirum Phar­ma­ceu­ti­cals.

Vir said Sun­day …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news